Stevanato Group (NYSE:STVN) Trading Down 5.3% - What's Next?

Stevanato Group S.p.A. (NYSE:STVN - Get Free Report)'s share price dropped 5.3% during trading on Wednesday . The stock traded as low as €18.07 ($19.64) and last traded at €18.30 ($19.89). Approximately 94,866 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 319,936 shares. The stock had previously closed at €19.32 ($21.00).

Wall Street Analysts Forecast Growth

STVN has been the subject of several research analyst reports. UBS Group decreased their price objective on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday. Bank of America raised their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research report on Friday. Morgan Stanley reissued an "equal weight" rating and set a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, Wolfe Research started coverage on shares of Stevanato Group in a research report on Friday, December 13th. They set an "outperform" rating and a $28.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Stevanato Group has an average rating of "Moderate Buy" and an average target price of €27.75 ($30.16).

Remove Ads

Stevanato Group Stock Up 4.9 %

The firm has a market cap of $6.58 billion, a price-to-earnings ratio of 46.21, a PEG ratio of 7.18 and a beta of 0.60. The business's 50 day moving average price is €21.38 and its 200 day moving average price is €20.55. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, hitting analysts' consensus estimates of €0.20 ($0.22). The business had revenue of €352.68 million for the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. On average, equities analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Institutional Investors Weigh In On Stevanato Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Zions Bancorporation N.A. acquired a new stake in Stevanato Group in the 3rd quarter valued at $1,049,000. Sivik Global Healthcare LLC acquired a new stake in Stevanato Group in the 3rd quarter valued at $2,800,000. King Wealth Management Group grew its stake in Stevanato Group by 30.2% in the 3rd quarter. King Wealth Management Group now owns 94,800 shares of the company's stock valued at $1,896,000 after acquiring an additional 22,000 shares during the period. Royce & Associates LP grew its stake in Stevanato Group by 45.8% in the 3rd quarter. Royce & Associates LP now owns 343,159 shares of the company's stock valued at $6,863,000 after acquiring an additional 107,869 shares during the period. Finally, Natixis Advisors LLC grew its stake in Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company's stock valued at $1,027,000 after acquiring an additional 8,669 shares during the period.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.